大学院保健学研究科
生体機能科学領域
■ 教授：渡邉 純
- 学位
- 医学博士
- 職位
- 教授
- 所属
- 保健学研究科生命科学領域
- 電話番号
- 0172-39-5967
- watajun
※アカウントの後に「@hirosaki-u.ac.jp」を加えてください。
学部
■ 専攻
検査技術科学専攻
■ 研究テーマ
・子宮内膜癌細胞における性ステロイドホルモンの作用機序解析
・子宮内膜癌の予後・予知因子の解析
・子宮頸癌の癌化機序解析
・組織細胞診検体の形態学的、分子病理学的およびデジタル画像解析
■ キーワード
細胞・組織病理学、婦人科腫瘍学
業績
■ 著書
1. Holinka,C.F., Anzai,Y. ,Hata,H., Watanabe,J. ,Kuramoto,H. and Gurpide,E. :Effects of hormones on endometrial cancer cells in culture. The Prime Endometrium, Volume 622 of the Annals of the New York Academy of Science, New York, 1991, pp.422-238.
2. Hata,H., Hamano,M., Watanabe,J., Tateoka,K. and Kuramoto.H. :Role of TFG-α in the mechanism of hormone dependency of endometrial carcinoma cells (Ishikawa). In vitro Biology of Sex Steroid Hormone action (eds. H.Kuramoto and E.Gurpide). Churchill Livingstone, Tokyo, 1996, pp158-170.
3.Watanabe,J., Kamata,Y., Kanai,T., Seo,N., Fujisama,T., Nishimura,Y., Hanamo,M., Jobo,T. and Kuramoto,H. :Expression of cell cycle regulators in endometrial adenocarcinoma. Cell and Molecular Biology of Endometrial Carcinoma (eds. H.Kuramoto and M.Nishida). Springer, Tokyo, 2003, pp93-106.
4. 蔵本博行、西村由香里、渡辺 純：TriPath社SurePath法によるThinlayer標本アトラス婦人科細胞診２．子宮内膜・内膜病変．ＭＢＬ医学生物学研究所発行、名古屋、2005年、pp43-75.
5. 渡辺 純：８．炎症と感染症（p59-66）、９．免疫と免疫異常（p67-73）、１６．生殖器系（p150-156）．医療系学生のための病理学第４版（中村仁志夫ら編）．講談社サイエンティフィック発行、東京、2010年．
■ 学術論文
1. Watanabe,J., Holinka,C.F., Anzai,Y., Kuramoto,H. and Gurpide,E. :Effects of serine and glycine on proliferation of an Ishikawa cell variant. J. steroid Biochem., 34:165-168, 1989.
2. 渡辺純、上坊敏子、秦宏樹、蔵本博行：子宮内膜症における血中ＣＡ19-9測定の臨床的意義 日本産科婦人科学会雑誌、42(2):155-161, 1990.
3. Watanabe,J., Sato,Y., Kuramoto,H. , Kameya,T. :Expression of nm23-H1 and nm23-H2 protein in endometrial carcinoma. Br. J. Cancer., 72:1469-1473, 1995.
4. Hata,H., Hamano,M., Watanabe,J. and Kuramoto,H.：Role of estrogen and estrogen-related growth factor in the mechanism of hormone dependency of endometrial carcinoma cells. Oncology, 55:35-44, 1998.
5. Watanabe,J., Sato,Y., Tsuchiya,B., Kuramoto,H. and Kameya,T.：Qualitative and quantitative assessment of modified in situ reverse transcription-polymerase chain reaction (in situ RT-PCR) method. Acta Histochem. Cytochem., 32(5):423-430, 1999.
6. Kanai,T., Watanabe,J., Kamata,Y., Hamano,M. and Kuramoto,H. :Stimulatory Effect of Medroxyprogesterone acetate on p27 Protein in Endometrial Cancer Cells. Kitasato Med. 31(6): 392-397, 2001.
7. Fujisawa,T., Watanabe,J., Akaboshi,M., Ohno,E. and Kuramoto,H. : Immunohistochemical study on VEGF expression in endometrial carcinoma – comparison with p53 expression, angiogenesis, and tumor histologic grade. J. Cancer Res. Clin. Oncol., 127: 668-674, 2001.
8. 赤星誠、渡辺純、藤澤武志、服部学、大野英治、蔵本博行：子宮内膜癌におけるcdk2およびKi-67発現に関する免疫組織化学的検討 日本臨床細胞学会雑誌、40(2):121-127, 2001.
9. 角田新平、上坊敏子、新井正秀、渡辺純、蔵本博行：子宮頸部小細胞癌の臨床病理学的検討 北里医学、32(5): 401-405, 2002.
10.Kyushima,N., Watanabe.J., Hata.H., Jobo.T., Kameya,T. and Kuramoto,T. :Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J. Cancer Res. Clin. Oncol., 128:307-312, 2002.
11.Watanabe, J., Sato,H., Kanai,T., Kamata,Y., Jobo,T., Hata,H., Fujisawa,T., Ohno,E., Kameya,T. and Kuramoto,H. Paradoxical Expression of cell cycle inhibitor p27 in endometrioid adenoccarcinoma of the uterine corpus – correlation with proliferation and clinicopathological parameters. Br. J. Cancer, 87:81-85, 2002.
12.Kato,N., Watanabe, J., Jobo,T., Nishimura,Y., Fujisama,T., Kamata,Y. and Kuramoto,H. :Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathologicalo significance. J. Cancer Res. Clin. Oncol., 129:222-226, 2003.
13.Fujisawa,T., Watanabe,J., Kamata,Y., Hamano,M., Hata,H. and Kuramoto,H. :Effect of p53 gene transfection on vascular endothelial growth factor expression in endometrial cancer cells. Exp. Mol. Pathol., 74:276-281, 2003.
14.Saegusa,M., Hamano,M., Kuwata,T., Yoshida,T., Hashomura,M., Akino,F., Watanabe,J., Kuramoto,H. and Okayasu, I. :Up-regulation and nuclear locarization of β-catenin in endometrial carcinoma in response to progesterone therapy. Cancer Sci., 94(1): 103-111, 2003.
15.Fujisawa,T., Watanabe,J., Kamata,Y., Hamano,M., Hata,H. and Kuramoto,H. :VEGF expression and its regulation by p53 gene transfection in endometrial carcinoma cells. Human Cell, 16:47-54, 2003.
16.Kamata,Y., Watanabe,J., Hata,H., Hamano,M.and Kuramoto,H. :Quantitative study on the correlation between p53 gene mutation and its expression in endometrial carcinoma cell lines. Eur. J. Gynaec. Oncol., 25: 55-60, 2003.
17.Kimura,F., Watanabe,J., Hata,H., Fujisawa,T., Kamata,Y., Nishimura,Y., Jobo,T. and Kuramoto,H. :PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J. Cancer Res. Clin. Oncol., 130: 161-168, 2003.
18.Watanabe,J., Nishizaki,R., Jobo,T., Kamata,Y., Hata,H., Nishimura,Y., Fujisawa,T., Okayasu,I. And Kuramoto,H. :Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus. Int.J. Gynecol. Pathol., 23:234-240, 2004.
19.Fujisawa,T., Hamano,M., Hata,H., Kamata,Y., Watanabe,J., Sekimoto,R. and Kuramoto,H. :Establishment and characterization of two different types of new human endometrial adenocarcinoma cell lines. Eur. J. Gynaec. Oncol. 25:299-304, 2004.
20.Nishimura,Y., Watanabe,J., Jobo,T., Kato,N., Fujisawa,T., Kamata,Y. and Kuramoto,H. :Cyclin D1 Expression in Endometrioid-type Endometrial Adenocarcinoma is Correlated with Histological Grade and Proliferative Activity, but not with Prognosis. Anticancer Res., 24:2185-2192, 2004.
21.Miyamoto, T., Watanabe,J., Hata,H., Jobo,T., Kawaguchi,M., Hattori,M., Saito,M. and Kuramoto,H. :Significance of progesterone receptor-A and –B expressions in endometrial adenocarcinoma. J. Seroid Biochem. Mol. Biol., 92:111-118, 2004.
22.Nishimura, Y., Watanabe, J., Jobo, T., Hattori, M., Arai, T. and Kuramoto, H.: Cytological scoring of endometrioid adenocarcinoma of the endometrium — correlation with histological grade and clinicopathological factors. Cancer Cytopathol., 105:8-12, 2005.
23.Tsunoda,S., Jobo,T., Arai,M., Imai,M., Kanai,T., Tamura,T., Watanabe,J., Obokata,A. and Kuramoto,H. :Small-cell carcinoma of the uterine cervix: a clinicopathologic study of 11 cases.Int. J. Gynecol.Cancer,15: 295-300, 2005
24.Kamata, Y., Watanabe, J., Nishimura, Y., Arai, T., Kawaguchi, M., Hattori, M., Obokata, A. and Kuramoto, H. :High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma. J. Cancer Res. Clin. Oncol., 131:591-596, 2005.
25.Arai, T., Watanabe, J., Kawaguchi, M., Kamata, Y., Nishimura, Y., Jobo, T and Kuramoto, H. :Clear cell adenocarcinoma of the endometrium is biologically a tumor with distinct entity from endometrioid adenocarcinoma. Int. J. Gynecol. Cancer, 16:391-395, 2006.
26.Watanabe,J., Watanabe,K., Jobo,T., Kamata,Y., Kawaguchi,M., Imai,M., Okayasu,I. and Kuramoto,H. :Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial carcinoma. Int.J.Gynecol.Cancer, 16:452-457, 2006.
27.Kawaguchi, M., Watanabe, J., Hamano, M., Arai, T., Nishimura, Y., Jobo, T. and Kuramoto, H. :Medroxyprogesterone Acetate stimulates cdk inhibitors, p21 and p27, in the endometrial carcinoma cells transfected with progesterone receptor-B cDNA. Eur. J. Gynaec. Oncol., 27:33-38,2006
28.Tamura, T., Jobo,T., Watanabe,J., Kanai,T., and Kuramoto.H. : Neuroendocrine features in poorly differentiated endometrioid adenocarcinomas of the endometrium.Int. J. Gynecol. Cancer, 16,:821-826,2006
29.Saito,M., Watanabe,J. Fujisawa,T., Kamata,Y., Nishimura,Y., Arai,T., Miyamoto,T., Obokata,A.and Kuramoto,H. :Angiopoietin-1,2 and Tie2 expressions in endometrial acenocarcinoma –colleration with its tumor angiogenesis. Eur. J. Gynaec. Oncol., 27:129-134, 2006
30.西村由香里、渡辺純、上坊敏子、川口美和、新井努、服部学、岡安勲、蔵本博行：Thinlayer法による子宮内膜細胞診－治療前予後判定の有用性－．日本臨床細胞学会雑誌、45:242-249, 2006
31.Obokata, A., Watanabe, J., Nishimura,Y., Arai, T., Kawaguchi, M., and Kuramoto, H. :Significance of matrix metalloproteinase-2, -11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplasia and neoplastic endometrium. Anticancer Res., 27:95-106,2007
32.Saito, M., Sato, Y., Watanabe, J., Kuramoto, H., Kaba, S. and Fukuda, T. : Angiogenic factors in normal endometrium and endometrial adenocarcinoma. Patol. Int., 57:140-147,2007
33.二井美津穂、渡辺 純、角田新平、上坊敏子、西村由香里、渡辺佳代子、岡安 勲、海野信也：Linear array HPV遺伝子検出法 ウォーターバス法とドライエアインキュベーター法の比較検討．臨床検査、51:1009-1012, 2007
34.Watanabe, J., Kamata, Y., Seo, N., Okayasu, I. and Kuramoto H. :Stimulatory effect of estrogen on the growth of endometrial cancer cells is regulated by cell-cycle regulators. J. Steroid Biochem. Mol. Biol., 107:163-171, 2007
35.町田大輔、西村由香里、横山大、豊永真澄、柿沼廣邦、服部学、山下和也、上坊敏子、渡辺純、岡安勲：Thinlayer標本による子宮内膜細胞診の評価．日本臨床細胞学会雑誌、47:95-102, 2008
36.Saegusa, M., Hashimura, M., Kuwata, T., Hamano, M., Watanabe, J., Kawaguchi, M. and Okayasu, I. :Transcription factor Egr1 acts as an upstream regulator of 
-catenin signalling through up-regulation of TCF4 and p300 expression during trans-differentiation of endometrial carcinoma cells. J. Pathol., 216 :521-532, 2008
37.Arai, M., Jobo, T., Miyamoto, T., Arai, T., Watanabe, J., Unno, N. and Kuramoto, H. Primary fallopian tube carcinoma is biologically different from endometrial adenocarcinoma. Kitasato Med.J., 39:18-23, 2009.
38.Watanabe, J.,Nishimura, Y., Tsunoda, S., Kawaguchi, M., Okayasu, I. and Kuramoto, H. Liquid-based preparation for endometrial cytology - Usefulness for predicting the prognosis of endometrial carcinoma preoperatively. Cancer Cytopathol., 117;254-263, 2009.
39.Futai, M., Watanabe, J., Jobo, T., Tsunoda, S., Nishimura, Y., Watanabe, K., Okayasu, I. and Unno, N. Clinical significance of human papillomavurus (HPV) genotype by linear array assay in Japanese women with uterine cervical lesions and type 16 physical status by in situ hybridization. Int. J. Gynecol. Cancer, 19:1396-1401, 2009.
40.Kimura, F., Kawamura, J., Watanabe, J., Kamoshida, S., Kawai, K., Okayasu, I. and Kuwao, S. Significance of Cell Proliferation Markers (Minichromosome Maintenance Protein 7, Topoisomerase IIα and Ki-67) in Cavital Fluid Cytology. – Can WeDifferentiate Reactive Mesothelial Cells from Malignant Cells? –. Diagn. Cytopathol. 38:161-167, 2010.
41.Niibe, Y., Watanabe, J., Tsunoda, S., Arai, M., Arai, T., Kawaguchi, M., Matsui, K., Jobo, T., Ono, S., Numata, A., Unno, N. and Hayakawa, K. Concomitant expression of HER-2 and HIF-1α is a predictor of poor prognosis in uterine cervical carcinoma treated with concurrent chemoradiotherapy: prospective analysis (KGROG0501). Eur. J. Gynaec. Oncol. 31:491-496, 2010.
42.Naoya, A., Watanabe, J., Tsunoda, S., Kuramoto, H. and Okayasu, I. Significance of nuclear p-Akt in endometrial carcinogenesis- Rapid translocation of p-Akt into the nucleus by estrogen, possibly resulting in inhibition of apoptosis. Int. J. Gynecol. Cancer, 21:194-202, 2011.
43.渡辺 純、鷲谷清忠、吉岡治彦：弘前大学大学院保健学研究科での細胞検査士養成課程の取り組み、課題と将来の展望．臨床検査学教育、3：11-15, 2011.
44.Washiya, K., Sato, T., Miura, T., Tone, K., Kojima, K., Watanabe, J., Kijima, K. Cytological difference between benignity and malignancy in suspicious cases employing uterine cytodiagnosis using ThinPrep method. Anal. Quant. Cytol. Histol., 33:169-174, 2011.
45.Washiya, K., Kanno, T., Tone, K., Kojima, K., Kijima, H., Watanabe, J. Three-dimensional nuclear luminance analysis in well-differentiated adenocarcinoma of the lung. Acta Cytol., 55:350-356,2011.
46.Washiya, K., Abe, I., Ambo, J., Iwai, M., Okusawa, E., Asanuma, K., Watanabe, J. Cytological analysis of atypical squamous epithelial cells of undetermined significance using the World Wide Web. Acta Cytol., 55:319-326, 2011.
47.Washiya, K., Takamizu, R., Kumagai, Y., Himeji ,Y., Kobayashi,T., Iwai, M., Watanabe, J. World Wide Web-Based Cytological Analysis of Atypical Squamous Cells Cannot Exclude High-Grade Intraepithelial Lesions. Acta Cytol. , 56:47-54, 2012.
48.Washiya, K., Noro, T., Narumi, K., Kurose, A., Yoshioka, H., Watanabe, J. Usefulness of discriminant analysis using nuclear 3 dimensional analysis in atypical cells prepared from bronchial brushing cytology cases that are cytologically challenging. Acta Cytol., 56: 297-303, 2012.
49.Washiya, K., Narumi, K., Noro, T., Hamakawa, S., Furuta, N., Yoshioka, H., Watanabe, J. Discriminant analysis of malignant mesothelioma and reactive mesothelium using three-dimensional nuclear estimation. Acta Cytol., 56:189-195, 2012.
&
■ 総説/解説
1. 蔵本博行、秦宏樹、加藤良樹、森沢孝之、秦和子、渡辺純、浜野美恵子、西田正人、鈴木光明、安西弦、Holinka,C.F., Gurpide,E. :細胞培養法を応用した子宮体癌のホルモン研究 産婦人科の世界：40(10):1037-1043, 1988.
2. 蔵本博行、加藤良樹、秦宏樹、秦和子、浜野美恵子、安西弦、渡辺純、Holinka,C.F., Gurpide,E. :子宮体癌のホルモン研究におけるin vitro 細胞システムの役割 産婦人科治療：58(2):231-236, 1989.
3. 蔵本博行、秦宏樹、渡辺純、浜野美恵子：子宮体癌−基礎から臨床へ Modern Medicine:21(5):63-72, 1989..
4. 蔵本博行、上坊敏子、大河原聡、辻井篤、渡辺純：体がんと検診−検診対象の拡大が望まれる 産婦人科治療、66(2):174-178, 1993.
5. 蔵本博行、上坊敏子、秦宏樹、渡辺純、立岡和弘、浜野美恵子：子宮体癌とステロイドホルモン Hormone Frontier in Gynecology, 3(1):47-52, 1996.
6. 渡辺純、秦宏樹、安西弦、蔵本博行：エストロゲンと子宮内膜癌・乳癌 現代医療、29(10):132-138, 1997.
7. 渡辺純、亀谷徹：in situ RT-PCR法 検査と技術、27(5):482-485, 1999.
8. 蔵本博行、新井正秀、新井努、後賢、林玲子、金井督之、今井愛、渡辺純：悪性疾患の予防・早期発見−子宮内膜癌 産科と婦人科、67(4):497-503, 2000.
9. 蔵本博行、鎌田裕子、西村由香里、新井努、川口美和、宮本朋幸、斉藤まゆみ、小保方亜光、渡辺純：子宮内膜癌と細胞周期遺伝子発現 癌の臨床、49(12): 1579-1586, 2003.
10.新部譲、角田新平、上坊敏子、今井愛、新井正秀、新井努、川口美和、渡辺純、浜田幸宏、矢後和夫、松尾恵太郎、海野信也、早川和重：北里婦人科放射線腫瘍研究グループの概略 北里医学、37(2): 131-134, 2007.
11.沼田彩、葛岡美津穂、新井正秀、新井努、川口美和、小野重満、渡辺純、角田新平、海野信也：HPV感染と子宮頸癌との関連性ーHPVワクチンの展望についてー 北里医学、40(1): 39-46, 2010.
12.方山揚誠、渡邉純、松榮恒一、齊藤俊夫：（１）細胞診材料の採取と採取直後の処理、第一部細胞診の基本 病理と臨床臨時増刊号、31：2-8、2013.
■ 社会活動
‐
■ 所属学会
・日本病理学会（専門医・評議員）
・日本産科婦人科学会（専門医）
・日本臨床細胞学会（専門医・評議員・査読委員・倫理委員会委員）
・国際細胞診学会（専門医：Fellow of International Academy of Cytology）
・日本婦人科腫瘍学会（評議員・査読委員）
・日本癌学会
・日本癌治療学会
・日本内分泌学会
・日本組織培養学会
・日本ヒト細胞学会
■ 備考
‐